Focus on Minimally Invasive Treatment of Cardiovascular Disease

The Cardiovascular system is vital for the health and well-being of our body. When affected by disease, it can undermine the function of many organs, seriously affect the whole body, reduce quality of life, and increase mortality.

The number of people dying from Cardiovascular Disease is steadily rising worldwide. Cardiovascular Disease was the underlying cause of one-third of all deaths globally in 2019, according to a state-of-the-art review published on Dec. 9 2020 in the Journal of the American College of Cardiology.

Duving the COVID-19 pandemic, there was a continuous high rate of excess mortality and morbidity. Much of the additional disease burden is due to Cardiovascular Disease, related to the impact of the pandemic on the efficiency of the health care systems, and the multiple short-and-long term effects of viral infection on the patients. These effects include pneumonia, acute respiratory syndrome and multi-vessel thrombosis, leading to chronic cardiovascular system damage in COVID-19 survivors.

Innovative minimally invasive treatments are urgently needed to properly address the above challenges, save lives, reduce morbidity, and improve the quality of life in the affected patients.

Flow Medical is developing minimally invasive endovascular medical devices designed to treat thrombosis related conditions in the vascular system. Our initial focus is the treatment of Deep Venous Thrombosis, and Peripheral Arterial Occlusions.